![2](https://www.srjnews.com/wp-content/uploads/2015/06/2.jpg)
Pfizer Inc. (NYSE:PFE) reported that enrollment of the first patient in a Phase 2b clinical examination of its investigational Staphylococcus aureus or S. aureus multi-antigen vaccine in adults undergoing elective spinal fusion surgery. The reason of the study, hired STRIVE, is to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective spinal surgery. The primary outcome of the study, with an estimated enrollment of 2600 subjects, will measure the number of subjects in each treatment group with postoperative S. aureus blood stream infections and/or deep incisional or organ/space surgical site infections occurring within 90 days after elective posterior instrumented lumbar spinal fusion. Pfizer Inc. (NYSE:PFE) stock price closed at $33.73 with the total traded volume of 25.85 Million shares. Its price to sales ratio ended at 4.17. Its market capitalization is 206.77 Billion. The stock owned by the Financial Institutions was 74.80% while by insiders was 0.10%.
MSC Industrial Direct Co. Inc. (NYSE:MSM) released that its Q3 GAAP net income of $63.3M, or $1.03 a share, as compared to $64.7M, or $1.03 a share, a year before. Excluding the after-tax effects of non-recurring costs, adjusted net income for the fiscal Q3 was $63.5M, or $1.03 per share. CFO, Jeff Kaczka said, “Despite the challenging demand environment, we achieved earnings per share well above our guidance range. A key driver was the prompt actions that we took to manage our operating expenses. We achieved operating expenses as a percent of sales at the same level as the year ago quarter, even though sales growth was only low single-digits and we increased our investment spending. The second driver was another quarter of gross margin stabilization, which reflected our successful countermeasure efforts, offset by the gross margin headwinds from large account growth and the soft pricing environment.” MSC Industrial Direct Co. Inc. (NYSE:MSM) begun last trade with a price of $69.50 and throughout the trading session climbed at a high of $69.83. The day-trade ended with 3.10% to $70.09. The stock is going forward to its 52 week low with 0.31% and lagging behind from its 52 week high price with -25.29%. MSM last month stock price volatility remained 1.19%.
Merck & Co. Inc. (NYSE:MRK) and Allergan plc (AGN) released that they have signed into an contract under which Allergan will purchase the exclusive worldwide rights to Merck’s investigational small molecule oral calcitonin gene-related peptide receptor antagonists, which are being developed for the treatment and prevention of migraine. Allergan will acquire these rights for an upfront payment of $250 million, $125 million of which is payable upon HSR clearance and $125 million of which is payable in April of 2016. Merck will additionally be entitled to receive potential development and commercial milestone payments and tiered double-digit royalties based on commercialization of the programs. Merck & Co. Inc. (NYSE:MRK) has the market capitalization of 162.73 Billion. Shares of firm surged 0.76% to close at $57.99 with the total traded volume of 9.03 Million. The firm has current ratio of 1.60 for the most recent quarter.